新興市場シリーズ：ブラジル、ロシア、インド、中国、トルコの医薬品市場ベンチマーキング

Abstract

Scope of the report

This report provides an introduction to the pharmaceutical markets in five key emerging markets. It comprises a review of the countries economic and political environment as well as more detailed analysis of the healthcare system and pharmaceutical market including key data and analysis of top companies and market size. The opportunities presented by the five markets for pharmaceutical companies are also benchmarked to provide insight into the relative attractiveness of each.

Table of Contents

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 INTRODUCTION TO EMERGING PHARMACEUTICAL MARKETS

• Why are emerging markets of interest now
  • Attractions - reasons to go
  • Reasons not to go
• Regions

CHAPTER 3 RUSSIAN PHARMACEUTICAL MARKET

• Demographic trends
  • Basic facts
  • Life expectancy
  • Ageing and depopulation
• Disease burden
• Healthcare system
  • Mandatory health insurance was introduced in 1991
  • Certain diseases have become a priority of the Russian government
  • Healthcare expenditure is below the level of Western EU countries
  • Primary vs hospital healthcare
  • Under the table spend
  • Access to healthcare is especially problematic for the poor population
  • Companies offering private health insurance are scarce and focus on the top end of the market
• Pricing and reimbursement of drugs
  • Pricing of drugs
  • Reimbursement
  • DLO
• Regulatory
  • Intellectual property protection
  • Patents
  • Data exclusivity
  • Counterfeiting
  • Registration of drugs
  • The majority of drugs are sold without a prescription.
• Socioeconomic environment
  • Economic
  • The Russian economy is trying to break away from overdependence on natural resources and is diversifying
  • The population is highly educated but the output is low
  • Looming labor shortage
  • Regional differences
  • Accession to WTO
  • Foreign investment
• Political climate
  • Russia remains a centralized country with the center of power in Moscow
  • Corruption
• Corporate
  • Bureaucracy- red tape
  • Registration of a legal entity in Russia is a long and costly procedure
  • Taxation differs for foreign companies
  • Customs
• Pharmaceutical market dynamics
  • The distribution segment is fragmented but is consolidating
  • The pharmacy networks segment is fragmented
  • Sales of pharmaceuticals
  • Global pharma lead the Russian pharmaceutical market by sales value
  • Retail sales
  • Hospital sales
  • DLO is one of the major growth drivers of the Russian pharmaceutical market
  • Import
  • Export
  • Launch, marketing and branding
  • Which drugs to market
  • Market entry strategies
• Major foreign players
  • Sanofi-Aventis is the top foreign pharmaceutical company in Russia
  • Novartis' s presence in Russia is growing
  • Servier
  • Roche
  • Gedeon Richter
  • Nycomed
  • Eli Lilly
  • Novo Nordisk
  • Bayer
  • Other Foreign companies are acquiring manufacturing facilities in Russia
• Major domestic players
  • Innovation is lagging behind the West
  • The Russian pharmaceutical market will continue to grow
• Manufacturing drugs in Russia
• Clinical trials

CHAPTER 4 TURKEY

CHAPTER 5 BRAZIL

CHAPTER 6 INDIA

CHAPTER 7 CHINA

CHAPTER 8 SCORECARDS FOR ANALYZED COUNTRIES - A FRAMEWORK FOR EMERGING MARKET ANALYSIS

CHAPTER 9 BIBLIOGRAPHY

APPENDIX

NOTE: Turkey, Brazil, India and China chapters will follow the same structure as Russia.